ERBB2 and esophageal cancer: As HER2 was found to be associated with adaptive radiation resistance, while HER2 inhibition was found to reduce radioresistance in breast cancer [6,7]; here, we examined whether pyrotinib could enhance the effect of radiation in esophageal cancer cells.